Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 8/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317146 | 0.82 | L3MBTL1 (0.42) | SLC6A9GAAL3MBTL1 | |
| SCHEMBL21938280 | 0.79 | GAA (0.56) | GAAL3MBTL1SOS1BRD4 | |
| SCHEMBL3314526 | 0.78 | CACNA2D1 (0.43) | GPR139BRD4 | |
| SCHEMBL3315968 | 0.75 | ADRB2 (0.48) | GAAL3MBTL1 | |
| SCHEMBL30672690 | 0.74 | GAA (0.55) | GAAL3MBTL1 | |
| SCHEMBL3317174 | 0.74 | HRH4 (0.39) | GAAL3MBTL1KMT2A | |
| SCHEMBL3317207 | 0.74 | CASR (0.42) | GAAL3MBTL1GPR139MEN1KMT2A | |
| SCHEMBL3315251 | 0.74 | ACACB (0.52) | GAAL3MBTL1MEN1KMT2A | |
| SCHEMBL3318604 | 0.73 | KDM1A (0.49) | MEN1KMT2A | |
| SCHEMBL3310959 | 0.72 | PANK3 (0.42) | GAAL3MBTL1GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | SLC6A9 666/4885GAA 4162/4885L3MBTL1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.